Skip to content
Nonprofiteer
← All organizations

CANARY FUND

EIN 65-1230251 WOODSIDE, CA

Largest nonprofits in California

Revenue 2025
$2,205,595
Expenses 2025
$2,185,417

Program services were 92.0% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

As filed

Subsection
03
NTEE code
T30
Classification
1000
Street
PO BOX 620134

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Other organizations at this address

1 other organization in the IRS Business Master File lists the same street address. matched by us

We match the street line and ZIP code as the IRS gives them, ignoring case and outer spaces and nothing else, so "AVE" and "AVENUE" count as different streets and this list can miss some. A shared address can mean related organizations or a shared office, but it can also be a registered agent, a mail drop or a service provider holding mail for unrelated clients. It is not, by itself, evidence that two organizations are connected.

Mission and programs · 2025

Mission

Canary Foundation is a public charity exempt from U.S. federal income tax under Section 501(c)(3) of the Internal Revenue Code in the United States. Canary Foundation of Canada is a Public Foundation registered with the Canada Revenue Agency; Business Number 82906 8550 RROOO1.The Canary Foundation has assembled teams of cancer researchers recognized by their peers as leaders in their disciplines from across multiple institutions and disciplines to attack the problem of early detection in a new, collaborative, action-oriented manner with the foremost objective of translating research into clinical applications. Canary differentiators include: * Dedication to early detection * Leaders in collaborative science * Focused and managed research * Best-in-class talent * 100% of donations goes to researchOne of the first decisions the Science Team made was to choose ovarian cancer as a prototype for creating an early detection blood test to detect trace amounts of proteins called biomarkers pro

Activities or mission (Part I)

Canary Foundation is the world's first non-profit organization dedicated solely to the funding, discovery and development of tests for early cancer detection.

  • The goal of the Canary Scientific Programs is to develop blood tests and imaging tests that can together be used to detect lethal cancers at a curable stage. Our plan for early and accurate cancer detection involves first screening patients with a blood test and then moving those patients who tested positive to a high-resolution imaging test to further isolate cancer so that it can be removed. Chances of survival are highest when cancer is detected before it spreads. Thus, accurate detection of cancer that would otherwise be lethal at its earliest stage promises to dramatically improve survival after diagnosis. Canary has supported research programs focused on solid tumor cancer types including ovarian, lung, pancreas and prostate cancers, as well as a Collaborations Program with collaborating early detection programs and centers that include the Canary Center at Stanford for Cancer Early Detection.

    Expenses $2,011,373 · Grants $1,760,069

  • Canary Ovarian Cancer Program: The goal of our ovarian research program is to develop a strategy to accurately identify ovarian cancers that would otherwise be lethal at a stage when they are readily curable. The program focuses on high grade serous ovarian cancer, which is the most common and lethal subtype, in order to have the highest impact on reducing ovarian cancer mortality. Our aims include understanding the earliest stages of cancer development in the fallopian tube, identifying molecular markers for early detection or prevention, and developing advanced imaging techniques for early detection of the disease. Development of blood and imaging tests follows a similar roadmap; both include biomarker discovery followed by validation, but they also involve different techniques and challenges.

  • Canary Lung Cancer Program:Canary is focused on developing diagnostics with high sensitivity and specificity to detect otherwise lethal lung cancers at a stage when they are readily curable. To this end, Canary has assembled a team of experts who are collaborating to discover and validate biomarkers for blood and imaging tests that together will identify individuals harboring lethal lung cancers so that they can be removed. The Canary Lung Cancer Program has supported the development and maintenance of critical biospecimen resources, blood biomarker discovery and validation, molecular imaging projects for early detection of lethal lung cancer, and epidemiology and modeling for effective lung cancer screening.(continued Sch O)

  • Canary Prostate Cancer Program:The specific goals of the Canary Foundation Prostate program are to develop tests that can: 1) Identify lethal prostate cancers at an early (curable) stage; 2) Classify prostate cancers as either 1) potentially lethal; best treated with aggressive therapy b) non-lethal: suitable for continued monitoring without aggressive treatment. Given the large body of published but invalidated candidate markers for prostate cancer, we are focusing our initial efforts on evaluating the performance of a selected set of promising biomarkers. Candidate biomarkers are evaluated based on their ability to detect lethal prostate cancers at an early (curable) stage and to discriminate lethal from non-lethal prostate cancer. We are considering both fluid-based and tissue-based biomarkers for prognostic applications. The Canary Prostate Active Surveillance Study (PASS) enrolls men who opt for active surveillance of their early stage prostate cancer. Men are followed closely for signs of cancer progression, donating biospecimens and clinical data for a minimum of 5 years or until receiving treatment for their disease. The biospecimens and clinical data provide a valuable resource to test promising biomarkers and predictive tools for their use in the active surveillance setting.Canary Pancreatic Cancer Program:Canary is focused on developing diagnostics with high sensitivity and specificity to detect otherwise lethal pancreatic cancers at an early stage when they can be cured through surgical resection. We anticipate that no single biomarker will be sufficient to create a test with the required sensitivity and specificity to detect pancreatic cancer early. Instead, a definitive diagnosis will rely upon combinations of biomarkers and upon blood and imaging tests used together. To this end, the Canary pancreatic cancer researchers have collaborated to discover and validate biomarkers that will provide the basis for blood and imaging tests for the early detection of pancreatic cancer. Canary Collaborations Program:Canary Foundation believes that a collaborative, coordinated approach is necessary to achieve our goals. Our multi-disciplinary, multi-institutional Early Detection Program provides a great example of this philosophy in action. Our foundation partnerships link mutual scientific expertise and entrepreneurial spirit in the hopes of advancing research in the diagnostic arena of early cancer detection. We partner with research institutions, foundations, industry and government organizations. Collaborating programs include the Canary Center at Stanford and the CRUK Cambridge Centre Early Detection Programme at the University of Cambridge in England. We provide scientific program management to make sure that all funded research activities among the scientists and clinicians at the various partner institutions are on track and that any obstacles are rapidly addressed and overcome.

As filed on the 2025 return. The filer continues this part on Schedule O, which is not shown here.

Officers and directors · 2025

As listed in Part VII of the 2025 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

  • Heidi Auman

    Program Manager

    Total calculated
    $201,750
    From this org
    $201,750
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $201,750
    Bonus
    not reported
    Other
    not reported
    Deferred
    not reported
    Nontaxable benefits
    not reported
    Filer's total
    $201,750

  • Don Listwin

    Founder & CEO

    Total calculated
    $0
    Hours/week
    8

  • Kevin Kennedy

    Treasurer

    Total calculated
    $0
    Hours/week
    4

  • Michael Ball

    Director

    Total calculated
    $0
    Hours/week
    4

  • Dale Jantzen

    Director

    Total calculated
    $0
    Hours/week
    4

  • Hilary Valentine

    Director

    Total calculated
    $0
    Hours/week
    4

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.

Filings

  • 2025
    Revenue
    $2,205,595
    Expenses
    $2,185,417
    Contributions
    $2,163,219
    Grants paid
    $1,760,069
  • 2024
    Revenue
    $1,792,816
    Expenses
    $1,727,013
    Contributions
    $1,755,058
    Grants paid
    $1,291,597
  • 2023
    Revenue
    $1,883,312
    Expenses
    $1,352,591
    Contributions
    $1,858,743
    Grants paid
    $881,040
  • 2022
    Revenue
    $2,494,481
    Expenses
    $1,374,478
    Contributions
    $2,494,411
    Grants paid
    $1,009,000

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

  • 2021 · 990

    Revenue
    $664,526
    Expenses
    $936,652
    Assets (EOY)
    $632,764

  • 2020 · 990

    Revenue
    $2,702,998
    Expenses
    $3,809,221
    Assets (EOY)
    $2,590,779

  • 2019 · 990

    Revenue
    $5,877,404
    Expenses
    $838,453
    Assets (EOY)
    $6,529,556

  • 2018 · 990

    Revenue
    $3,072,122
    Expenses
    $2,446,360
    Assets (EOY)
    $3,575,137

  • 2017 · 990

    Revenue
    $2,745,404
    Expenses
    $2,907,402
    Assets (EOY)
    $3,897,958

  • 2016 · 990

    Revenue
    $2,222,535
    Expenses
    $3,008,557
    Assets (EOY)
    $9,262,055

  • 2015 · 990

    Revenue
    $3,326,456
    Expenses
    $6,955,688
    Assets (EOY)
    $10,651,818

  • 2014 · 990

    Revenue
    $9,257,529
    Expenses
    $2,189,673
    Assets (EOY)
    $13,709,562

  • 2013 · 990

    Revenue
    $1,879,764
    Expenses
    $2,467,782
    Assets (EOY)
    $9,626,774

  • 2013 · 990

    Revenue
    $1,879,764
    Expenses
    $2,467,782
    Assets (EOY)
    $9,626,774

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all. Showing the 10 most recent; the API carries the rest.

Grants made

The 10 largest by cash amount. The API serves every itemized grant.

Where these grants went next →

Grants received

The 10 largest by cash amount. The API serves every itemized grant.

Other IRS files

Auto-Revocation List

Not listed. The IRS publishes this list for organizations whose exemption was automatically revoked for failing to file for three consecutive years.

Publication 78

Listed as of 13 October 2026, under deductibility PC.

These are two separate IRS files on two separate schedules, shown as published and not reconciled with each other. Neither is a statement about whether a contribution is deductible today: 19,245 organizations appear in Publication 78 while the IRS's own revocation file lists them as currently revoked, more than half of those revoked before 2019. Absence from Publication 78 is evidence of nothing, and presence is not evidence either. Verify current status with the IRS before relying on it.

What this page reflects

The registration facts above come from the IRS Business Master File published 13 October 2026 and read 1 November 2026, for every organization at once. Returns through tax year 2025, the newest we have parsed for this organization.